66
Views
8
CrossRef citations to date
0
Altmetric
Original

KALA-AZAR ASSOCIATED WITH COOMBS-POSITIVE AUTOIMMUNE HEMOLYTIC ANEMIA IN THE PATIENTS COMING FROM THE ENDEMIC AREA OF THIS DISEASE AND SUCCESSFUL TREATMENT OF THESE PATIENTS WITH LIPOSOMAL AMPHOTERICIN B

, MD, , MD & , MD
Pages 349-355 | Received 29 Oct 2003, Accepted 03 Oct 2005, Published online: 09 Jul 2009
 

Abstract

Kala-azar is an intracellular parasitic infection that infects and multiplies in the macrophages of the liver, the spleen, and the bone marrow. It is characterized by intermittent fever, hepatosplenomegaly, pancytopenia, and hypergammaglobulinemia. Although anemia is a usual finding, Coombs-positive autoimmune hemolytic anemia (AIHA) has rarely been reported with this disease. Pentavalent antimonial compounds remain the mainstay of treatment worldwide. Liposomal amphotericin B (L-AmB) is currently preferred in the treatment of kala-azar because of the resistance to pentavalent antimonals. The authors diagnosed kala-azar associated with Coombs-positive AIHA in 3 patients and treated them with L-AmB (1–5 mg/kg/day) for 30–36 days. Now, all of these patients are healthy following up at the outpatient base for 18–34 months. Kala-azar must be considered in patients with Coombs-positive AIHA and living in and coming from the endemic region for this disease, and it can be successfully treated with L-AmB.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.